Alhemo access in Bangladesh: the DGDA named-patient pathway
How patients in the People's Republic of Bangladesh legally obtain Alhemo (concizumab-mtci) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Quick orientation
Patients in Bangladesh access Alhemo (concizumab-mtci) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adolescent and adult patients with haemophilia A with FVIII inhibitors or haemophilia B with FIX inhibitors through the DGDA named-patient pathway, a Directorate General of Drug Administration-administered mechanism that allows a Bangladeshi-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in BDT.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Reserved for you.
Why Bangladeshi patients need Alhemo through the named-patient pathway
The People's Republic of Bangladesh operates a structured pharmaceutical regulatory environment. Alhemo (concizumab-mtci) is regulated through DGDA (Directorate General of Drug Administration) channels, and a Bangladeshi family asking for Alhemo is rarely asking for a medicine that does not exist locally. They are usually asking for a precise version of it that the local market has not caught up to.
Four converging patterns drive these cases. First, indication lag. Alhemo's newer FDA-approved indications and dosing expansions often reach local registration 12 to 36 months after the US label. A family whose treating physician has documented a clear FDA-label fit may still find that the local label has not caught up. Second, presentation gaps. The exact strength, weight-banded dose, or pen format the prescriber needs may not be stocked at the local agent even when the medicine is registered. Third, payer denial. out-of-pocket cash with Green Delta Insurance, MetLife Bangladesh, and Pragati Insurance health plans each assess specialty therapies case by case, and step-therapy or formulary rules often produce denials even when the drug is on the local register. Cash-pay families pursue cross-border supply rather than wait through appeals. Fourth, continuity of supply. When a US-stable patient relocates to Bangladesh or visits family for an extended period, maintaining the original FDA-sourced regimen matters more than switching to a different local presentation.
In each pattern, the DGDA named-patient pathway is the mechanism that connects a Bangladeshi-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific patient. Clinically, Alhemo is a humanised anti-tissue-factor-pathway-inhibitor (anti-TFPI) monoclonal antibody administered by daily subcutaneous injection that restores thrombin generation in the absence of factor replacement by neutralising TFPI, and the named-patient route preserves that mechanism rather than substituting a non-equivalent local option.
Current regulatory status of Alhemo in Bangladesh
Alhemo (concizumab-mtci, Novo Nordisk) is an anti-tissue-factor-pathway-inhibitor monoclonal antibody for prophylaxis in adolescents and adults with haemophilia A or B with neutralising inhibitors against FVIII or FIX. As of 2026-05-31, no public record of a DGDA marketing authorisation for concizumab has been identified on the DGDA Registered Imported Drugs list. Concizumab is a relatively recent FDA approval (2025) and Bangladesh has not, to public knowledge, completed a local registration as of the snapshot date.
Access for a Bangladeshi inhibitor patient therefore proceeds under Section 13 of the Drugs (Control) Ordinance 1982 through a case-by-case import permission letter issued by the Director General, DGDA. The institutional channel - typically routed through BSMMU Haematology, Dhaka Shishu Hospital paediatric haematology, or NICRH where adult inhibitor cases overlap with concomitant oncology - is the most common path, because the hospital pharmacy can act as institutional importer of a refrigerated biologic that requires 2 to 8 degree Celsius storage end-to-end.
Concizumab is administered by once-daily subcutaneous injection after an initial loading dose, so the file specifies multi-month supply per shipment rather than a single dose. DGDA does not publish a fixed SLA for these files; non-emergency haemophilia files filed through a tertiary hospital pharmacy commonly take several weeks. The route requires a BMDC-registered haematologist as the prescribing physician (Section 14A of the 1982 Ordinance prohibits prescription of unregistered medicines by other practitioners).
Last DGDA bulletin observed touching imported biologic regulation: 2025-01-14 Guideline for Quality Assurance of Locally Sourced Medical Products. Last verified by ARCH-74: 2026-05-31.
Named tertiary centres in Bangladesh where Alhemo is dispensed
Concizumab is a haematology drug; named-patient files concentrate at centres with adolescent and adult haemophilia inhibitor cohorts:
- Bangabandhu Sheikh Mujib Medical University (BSMMU), Shahbag, Dhaka - Department of Haematology and Department of Paediatric Haematology and Oncology; the principal national academic haematology referral centre with inhibitor-management experience.
- Dhaka Shishu Hospital (Bangladesh Shishu Hospital and Institute), Sher-e-Bangla Nagar, Dhaka - paediatric haematology service handling adolescent inhibitor cases prior to adult transition.
- Dhaka Medical College Hospital, Dhaka - Department of Haematology; large-volume public tertiary.
- Combined Military Hospital (CMH), Dhaka - haematology service for military families and selected civilian patients.
- Square Hospitals Limited, Panthapath, Dhaka - private multi-specialty tertiary; haematology consultant roster published on the hospital site.
The Haemophilia Society of Bangladesh (a patient-organisation distinct from the regulator) coordinates with BSMMU on inhibitor-case planning; its directory is a starting point for families whose physician needs the local referral chain.
Local pricing reference for Alhemo in Bangladesh
US WAC reference for Alhemo (concizumab-mtci, 15 mg/1.5 mL and 60 mg/1.5 mL prefilled pens) is in the order of USD 50,000 to USD 65,000 per month of prophylaxis at the FDA-labelled weight-banded daily-subcutaneous regimen for an adolescent or adult patient. The reference range is taken from US WAC sources on which Novo Nordisk lists the product; the FDA prescribing information is the dosing source. Source: FDA Drugs@FDA database.
No public BDT reference price for concizumab has been observed on DGDA, BSMMU, or Novo Nordisk Bangladesh published lists as of 2026-05-31. Importers customarily quote BDT at the spot USD/BDT rate published by Bangladesh Bank on the day of the proforma invoice. We do not estimate a BDT figure in this guide; an itemised quotation with day-of-quote conversion is issued at intake.
Price snapshot date: 2026-05-31. Cost of concomitant inhibitor management (Bethesda titre testing, breakthrough-bleed treatment with bypassing agent, monitoring) is separate from the concizumab line and is locally sourced.
Country-specific access barriers for Alhemo in Bangladesh
The principal barrier for concizumab in Bangladesh is cold-chain logistics rather than DGDA paperwork. The product requires continuous 2 to 8 degree Celsius storage through the international shipping leg and at the dispensing hospital pharmacy, with documented temperature monitoring. Dhaka customs handles refrigerated pharmaceutical clearance routinely, but smaller dispensing centres outside Dhaka and Chattogram do not always have validated cold-chain receiving infrastructure; the import file therefore typically names a Dhaka-based tertiary hospital pharmacy as the importer.
Public-sector funding posture for haemophilia inhibitor prophylaxis in Bangladesh is severely constrained. The Ministry of Health and Family Welfare does not maintain a national haemophilia prophylaxis programme funding novel anti-TFPI therapy as of 2026-05-31, although the World Federation of Hemophilia (WFH) Humanitarian Aid Program supplies bypassing-agent and FVIII/FIX-concentrate donations through national member organisations including the Haemophilia Society of Bangladesh. Case-by-case grant applications to the Honourable Prime Minister's Welfare Fund are the principal high-cost-medicine route for individual patients lacking means.
Private health insurance penetration is low in Bangladesh. Group-corporate policies (Pragati Life, Delta Life, MetLife Bangladesh, Green Delta) cover formal-sector employees; coverage of unregistered named-patient imports of a high-cost biologic is policy-specific and almost always subject to annual maximums that fall well below the concizumab annual cost. The dominant funding pattern is patient self-pay, family savings and remittances, charitable channels, and pharma compassionate-access enrolment where Novo Nordisk's regional patient-access programme accepts a Bangladesh-based file.
Because concizumab is a continuous-prophylaxis therapy, each new DGDA permission letter covers a defined supply period (a single quarter is a common scope); chronic-therapy patients re-apply per cycle. The institutional pharmacy track is materially easier than the personal-import track for any patient on continuous prophylaxis.
Recent local regulatory news touching Alhemo or its drug class in Bangladesh
No DGDA bulletin specifically naming concizumab or the anti-TFPI class has been observed in the last twelve months on the DGDA all-categories notices page as of 2026-05-31. The following adjacent developments are relevant context:
- 2025-01-14 - DGDA published the Guideline for Quality Assurance of Locally Sourced Medical Products; the guideline affects how biologic-product lots routed through the institutional-import channel are QA-checked at the hospital pharmacy. Source: DGDA Guideline PDF.
- The Bangladesh medicine-regulation reform Bill in active consultation may rename or restructure the institutional-import administrative carve-out that currently underpins haemophilia-inhibitor biologic access. Source: Dhaka Tribune coverage.
What your physician needs to provide
For a Bangladeshi-licensed specialist prescribing Alhemo through the DGDA pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's confirmed diagnosis for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adolescent and adult patients with haemophilia A with FVIII inhibitors or haemophilia B with FIX inhibitors, severity assessment (scoring instrument, biomarker, imaging, or biopsy as appropriate for the indication), prior therapy history including first-line options tried, and a clinical rationale for why Alhemo is the appropriate next step given a humanised anti-tissue-factor-pathway-inhibitor (anti-TFPI) monoclonal antibody administered by daily subcutaneous injection that restores thrombin generation in the absence of factor replacement by neutralising TFPI.
The letter also specifies the exact dosing plan per the FDA-approved label: starting dose, maintenance dose, route of administration, schedule, and intended duration of therapy. Monitoring plan should reference any baseline laboratory or imaging requirements specific to Alhemo (full blood count, liver function, infection screen, ophthalmology assessment, or pregnancy testing where the FDA label requires it), planned follow-up intervals, and dose-modification criteria for the most common adverse events.
The treating physician's Bangladeshi license number, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. For cold-chain or specialty-handling products, the dispensing pharmacy's documented storage protocol and continuous-temperature-monitoring log are part of the chain-of-custody record we share with the importer.
Common questions about Alhemo in Bangladesh
Will out-of-pocket cash with Green Delta Insurance, MetLife Bangladesh, and Pragati Insurance health plans cover this? Each insurer assesses named-patient imports case by case. Some reimburse fully when Alhemo is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.
Is the FDA-approved indication recognised by DGDA? The DGDA named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; DGDA review focuses on the clinical justification rather than re-litigating the FDA decision.
My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine? Any Bangladeshi-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Bangladesh Medical and Dental Council (BMDC) and the DGDA verifies the active license; the DGDA application records both the prescribing physician and the dispensing facility.
Can I receive Alhemo at home? The dispensing facility must be Bangladeshi-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.
What about competitors or alternative therapies in the same class? Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.
Where Reserve Meds fits in Alhemo cases
Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace DGDA, and we do not replace your dispensing pharmacy. For Alhemo specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Bangladesh, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.
Operationally, a typical Alhemo case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the DGDA application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.
Bangladeshi tertiary specialty care concentrates at Square, Apollo Imperial, United, Evercare, and Labaid in Dhaka; the DGDA named-patient import authorisation is the standard mechanism for unregistered specialty medicines and is typically filed by the treating consultant at one of these centres.
Next step
If your Bangladeshi physician has prescribed Alhemo and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.